ArticleTranslational vision science & technology2026
HDGF as a Novel Serological Marker for Proliferative Diabetic Retinopathy: A Mendelian Randomization and Cross-Sectional Study.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify novel serum biomarkers to improve the diagnosis of proliferative diabetic retinopathy (PDR) and to assist the development of advanced treatment strategies. Methods: A Mendelian randomization (MR) analysis was conducted using a Genome-Wide Association Studies database to assess the causal relationship between serum HDGF levels and three retinopathy phenotypes: any diabetic retinopathy (DR), non-proliferative DR (NPDR), and PDR. A total of 65 diabetic patients were recruited including diabetic patients without DR (NDR), those with NPDR, and those with PDR, as well as 22 non-diabetic healthy controls (CON). Serum HDGF concentrations across all groups were quantified via a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). Results: The MR analysis revealed a significant positive causal association between the serum HDGF levels and PDR (odds ratio [OR] = 1.083; 95% confidence interval [CI], 1.007-1.163; P = 0.029). Furthermore, ELISA results revealed a progressive increase in serum HDGF levels, with the lowest concentrations observed in the CON group, followed by the NDR, NPDR, and PDR groups (highest levels). Significant differences were observed in selected pairwise comparisons, particularly between PDR and non-PDR groups. Conclusions: Our study establishes a positive causal relationship between serum HDGF levels and PDR. Furthermore, serum HDGF levels exhibit a progressive upward trend in DR patients, with levels increasing with disease severity. These results suggest HDGF as a potential biomarker for PDR. Translational Relevance: This study reveals a positive causal relationship between serum HDGF levels and PDR, providing potential therapeutic targets for disease prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.